Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

23 déc. 2025 05h00 HE | Source: InnoCare Pharma

InnoCare Announces NMPA Approval of a Phase II Clinical Trial of TYK2 Inhibitor ICP-488 for Cutaneous Lupus Erythematosus

CLE is the second indication InnoCare is developing for ICP-488, and enrollment for the phase III study of ICP-488 for psoriasis is nearing completion.
17 déc. 2025 13h00 HE | Source: American Society for Dermatologic Surgery

Kavita Mariwalla, MD, Begins ASDS/A Presidential Year

Schaumburg, IL, Dec. 17, 2025 (GLOBE NEWSWIRE) -- The American Society for Dermatologic Surgery (ASDS) is pleased to introduce its new President, Kavita Mariwalla, MD, who began serving her one-year...
14 déc. 2025 04h49 HE | Source: InnoCare Pharma

InnoCare Announces Achievement of Primary Endpoint in Phase IIb Study of Orelabrutinib for SLE and Approval of Phase III Clinical Trial

Orelabrutinib demonstrated outstanding efficacy and well-tolerated safety profile in patients with SLE who had received 48 weeks of treatment.
10 déc. 2025 08h30 HE | Source: Journey Medical Corporation

Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology

Clinical trial achieved all three primary objectives with no significant safety issues being reported Results indicate that Emrosi can be safely used for up to 16 weeks with no detectable impact on...
28 nov. 2025 00h28 HE | Source: SNS Insider pvt ltd

Atopic Dermatitis Drugs Market to Reach $29.43 Billion by 2032, Driven by Rising Disease Prevalence & Strong Therapeutic Innovation | SNS Insider

Austin, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Atopic Dermatitis Drugs Market Size & Growth Analysis According to by SNS Insider, the Atopic Dermatitis Drugs Market size was valued at USD 14.93...
27 nov. 2025 20h55 HE | Source: InnoCare Pharma

InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis

InnoCare's pipeline under development now covers ten major autoimmune diseases, with a particular focus on dermatological conditions.
25 nov. 2025 01h00 HE | Source: Regeneron Pharmaceuticals, Inc.

Dupixent® (dupilumab) Approved as the First Targeted Medicine in the European Union (EU) in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years...
20 nov. 2025 07h58 HE | Source: BCC Research LLC

Global Hyaluronic Acid in Healthcare Market to Reach $10.5 Billion by 2030

Boston, Nov. 20, 2025 (GLOBE NEWSWIRE) -- According to the latest study from BCC Research, “Hyaluronic Acid in Healthcare: Global Markets” is projected to grow from $8 billion in 2025 to $10.5...
19 nov. 2025 10h50 HE | Source: Research and Markets

Dermatology Collaboration and Licensing Agreements Analysis Report and Directory 2025: Upfront, Milestone, and Royalties for 476 Deals by Company A-Z, Therapy Focus and Technology Type

Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Dermatology Collaboration and Licensing Deals 2016-2025" report has been added to ResearchAndMarkets.com's offering.Fully revised and updated, the...
18 nov. 2025 04h05 HE | Source: Research and Markets

Vitiligo Market Analysis Report 2025-2035: Targeted Therapies Like Biologics, Oral Medications, and Advanced Topicals Bolster Growth

Dublin, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The "Vitiligo Market - A Global and Regional Analysis: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035" report has been added to ...

Page suivante